Is delayed diagnosis in the UK to blame for poorer cancer outcomes?
Pertuzumab in HER2+ breast cancer
Gunter von Minckwitz
The importance of lifestyle intervention trials in cancer survivors
Introducing the National Optimal Lung Cancer Pathway (NOLCP) in the UK
Acute oncology: new immunotherapy guidelines